KA
EBS icon

Kerrisdale Advisers’s Emergent Biosolutions EBS Stock Holding History

Kerrisdale Advisers’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-29,969
Closed -$1.73M – 68
2020
Q1 		$1.73M Buy
+29,969
New +$1.73M 0.33% 43

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kerrisdale Advisers's EBS Position: Q2 2020 in Review

Kerrisdale Advisers sold out of Emergent Biosolutions (EBS) in Q2 2020, closing a stake of 29,969 shares — an estimated $1.73M sold.

Kerrisdale Advisers first reported a position in EBS in Q1 2020 and held it in 1 quarter. The position peaked at $1.73M in Q1 2020. 299 funds tracked by Wall St. Rank hold EBS as of Q2 2020.

  • Kerrisdale Advisers reported no remaining Emergent Biosolutions position as of Q2 2020 after selling out during the quarter.
  • Kerrisdale Advisers sold 29,969 Emergent Biosolutions shares in Q2 2020, an estimated $1.73M.
  • Kerrisdale Advisers first reported a position in Emergent Biosolutions in Q1 2020 and held it in 1 quarter.
  • Kerrisdale Advisers's Emergent Biosolutions position peaked at $1.73M in Q1 2020.
  • 299 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2020.

Based on Kerrisdale Advisers's 13F filing for Q2 2020, filed 14 Aug 2020.